Equine gastric disease treatment is getting more targeted

Treatment approaches for equine gastric disease are evolving toward a more tailored model, with clinicians increasingly separating management of equine squamous gastric disease, or ESGD, from equine glandular gastric disease, or EGGD. That distinction is reflected in recent educational coverage from The Horse and in the underlying literature: diagnosis by gastroscopy remains the standard, omeprazole still anchors pharmacologic therapy, and management changes are no longer treated as optional add-ons. (thehorse.com)

That shift has been building for years. The 2015 European College of Equine Internal Medicine consensus statement warned against treating presumed ulcers without prior gastroscopy when possible, noting that clinical signs are nonspecific and that distinguishing ESGD from EGGD is important before starting therapy. Since then, reviews and expert commentary have pushed the field further, especially as practitioners have recognized that glandular lesions are often more complex, less predictably responsive, and more tightly linked to stress, exercise intensity, and mucosal defense failure than classic squamous disease. (pmc.ncbi.nlm.nih.gov)

The treatment picture remains clearest for ESGD. Omeprazole is still widely described as the mainstay because acid suppression improves the environment for healing, but newer discussion has focused on how administration affects response. The Horse reported expert commentary that feeding can materially reduce omeprazole absorption, with fasting before dosing and delaying feed afterward potentially improving drug effect in some horses. Review data also show that treatment works best when paired with management changes, particularly more consistent forage access outside the dosing window, lower-starch feeding strategies, and recurrence prevention after the treatment course ends. (thehorse.com)

For EGGD, the picture is less straightforward. The Horse notes that omeprazole and misoprostol are key components of treatment, with some horses also needing adjunctive agents such as sucralfate. That fits with broader literature suggesting glandular disease is not simply an acid-exposure problem and may reflect impaired mucosal defense and inflammation. In a University of Illinois summary of controlled work in fasted horses receiving flunixin, omeprazole performed better than sucralfate monotherapy for both squamous and glandular lesion scores, while sucralfate alone did not appear effective for preventing glandular disease in that setting. (thehorse.com)

Research into adjunctive products is active, but the evidence is still mixed. A recent blinded, randomized, placebo-controlled trial summarized on PubMed tested a nutraceutical containing lecithin, pectin, and meadowsweet after omeprazole treatment to see whether it could prevent recurrence of ESGD and EGGD. Thirty horses with a recent diagnosis and treatment history for both lesion types were kept in their home environments and trained normally during the 4- to 8-week study. The nutraceutical was not superior to placebo on repeated gastroscopy, and recurrence was common: only five horses remained ulcer-free at the end of the trial regardless of group assignment. The nutraceutical group did show lower salivary ADA and higher bicarbonate concentrations at the final exam, but the investigators noted that these salivary biomarkers still require further validation. In practical terms, that means nutraceuticals may generate interest, but they haven’t yet displaced evidence-based pharmacologic treatment and management correction. (pubmed.ncbi.nlm.nih.gov)

Expert commentary also reinforces that diagnosis and treatment response don’t always line up neatly with clinical signs. The consensus statement notes that appetite changes, behavior changes, recurrent colic, and poor performance can be seen, but they’re not specific enough to reliably identify ulcer type or even confirm gastric disease. That matters for equine practitioners because pressure from pet parents and trainers to start treatment empirically can be high, especially in performance horses, yet the literature keeps pointing back to gastroscopy as the best way to guide therapy and avoid oversimplified ulcer management. (pmc.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, this is a reminder that equine gastric disease is increasingly a precision-management problem, not just an acid-suppression problem. ESGD and EGGD differ in pathophysiology, risk factors, treatment response, and recurrence patterns. That affects case workups, client communication, medication timing, feed recommendations, exercise planning, and follow-up. It also underscores the need to discuss NSAID exposure, fasting periods, transport, training intensity, and environmental stress when building a treatment plan, rather than assuming a standard omeprazole course will solve every case. The recurrence data from the nutraceutical trial add another practical point: stopping pharmacologic treatment can leave many horses vulnerable to relapse, even when they remain in familiar home and training settings. (vetmed.illinois.edu, pubmed.ncbi.nlm.nih.gov)

What to watch: The next phase of this story will likely center on better lesion-specific protocols, stronger evidence for adjunctive therapies in glandular disease, and more data on how dosing strategy, feeding management, and post-treatment maintenance affect recurrence in real-world equine practice. Nutraceuticals may remain part of that conversation, but current controlled evidence suggests any benefit is more likely to appear first in exploratory biomarker work than in clearly improved gastroscopic outcomes. (pubmed.ncbi.nlm.nih.gov)